Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Coordination and Support Action · Running

JOIN4ATMP Map, Join and Drive European Activities for Advanced Therapy Medicinal Product Development and Implementation for Patient and Society Benefit

Coordinator
Charite - Universitaetsmedizin Berlin, Germany
Runs
1 January 2024 to 31 December 2026
Status
Running
EU funding
€3.0m
Total cost
€3.4m
Partners
14 organisations in 9 countries
Type
Coordination and Support Action
Grant agreement
101137206

What the project is doing

In the project's own words, from its summary on CORDIS.

Advanced Therapy Medicinal Products (ATMPs) are medicines based on genes, cells and tissues for human use. They can provide patients novel treatment alternatives to significantly improve or even cure diseases that currently have no or inadequate standard-of-care options. However, significant challenges remain for the scientific, clinical and patient communities as well as commercial entities and regulatory, policy-making and technology-assessing bodies.

The JOIN4ATMP consortium unites international experts and stakeholders with the mission to accelerate and de-risk European ATMP development and ensure wide-spread equitable ATMP access for patients with common diseases, rare non-cancer diseases and rare cancers in Europe. It brings together all members of the European University Hospital Alliance with the existing EU-funded T2EVOLVE and RESTORE networks, and with active support from industry partners and patient representatives as our 14 core partners.

The core partners are joined by supporting partners active in ATMP development, production, application and regulation. Our team will use real-world data and experiences to achieve the most rapid and holistic map of current hurdles and the best way to improve support and regulation of ATMP development and use in the EU and associated countries. The JOIN4ATMP end-product will be a state-of-the-art information package circumscribing (i) currently existing and potential future hurdles preventing rapid and streamlined ATMP development and clinical translation and (ii) a defined set of recommendations to overcome these hurdles in a manner guaranteeing equitable access for patients throughout Europe.

We are committed to the long-term operation of our network and take steps to assure its sustainability in order to inform and coordinate activities in Europe for the ATMP field, which will only gain in importance with the advance of personalized medicine in the future.

Topics

Who is involved

OrganisationCityCountryRole
Charite - Universitaetsmedizin BerlinBerlinGermanyCoordinator
Medizinische Universitaet WienWienAustriaParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyParticipant
Aarhus UniversitetshospitalAarhusDenmarkParticipant
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Eurordis - Rare Diseases EuropeParisFranceParticipant
Fondazione Telethon EtsRomaItalyParticipant
Universita Vita-Salute San RaffaeleMilanoItalyParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Region StockholmStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI